|
|
Article: Abraxis BioScience Launches Abraxane[R] in European Union.
- Article from:
- Business Wire
- Article date:
- December 15, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Initial Product Launch in the UK, Followed by Germany in Q1 2009
LOS ANGELES & LONDON -- Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced the launch in the European Union of Abraxane([R]) Paclitaxel 5 mg/ml powder for suspension for infusion. Abraxane([R]) is an albumin-bound nanoparticle formulation of paclitaxel. In the EU, Abraxane([R]) is indicated for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
"The launch of Abraxane([R]) in the EU, initially in the ...